Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 29;86(4):287-290.
doi: 10.1016/j.jacc.2025.04.069.

Anticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage: A Meta-Analysis of Randomized Trials

Kuan-Yu Chi  1 , Yu Chang  2 , Pei-Lun Lee  1 , Raiza Rossi  3 , Yu-Shiuan Lin  4 , Zafer Akman  3 , Dimitrios Varrias  3 , Abdulla A Damluji  5 , Michael G Nanna  6
Affiliations

Anticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage: A Meta-Analysis of Randomized Trials

Kuan-Yu Chi et al. J Am Coll Cardiol. .
No abstract available

Keywords: anticoagulation; atrial fibrillation; intracranial hemorrhage; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Damluji receives research funding from the Pepper Scholars Program of the Johns Hopkins University Claude D. Pepper Older Americans Independence Center funded by the National Institute on Aging P30-AG021334; a mentored patient–oriented research career development award from the National Heart, Lung, and Blood Institute (K23-HL153771); the NIH National Institute of Aging (R01-AG078153); and the Patient-Centered Outcomes Research Institute (PCORI). Dr Nanna receives research support from the American College of Cardiology Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342), and the National Institute on Aging (K76AG088428); and serves as a consultant for Novo Nordisk, Merck, and HeartFlow, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

FIGURE 1
FIGURE 1. Summary of Trial Characteristics and Study Endpoints Between OAC Use vs No Use
*Mean value. APACHE-AF = Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation study; ICH = intracranial hemorrhage; MH = Mantel-Haenszel test; NASPAF-ICH = NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH study; NNH = number needed to harm; NNT = number needed to treat; OAC = oral anticoagulants; PRESTIGE-AF = PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation trial; RCT = randomized controlled trial; SoSTART = Start or STop Anticoagulants Randomised Trial.
See this image and copyright information in PMC

References

    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. - PubMed
    1. Al-Shahi Salman R, Stephen J, Tierney JF, et al. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. Lancet Neurol. 2023;22(12): 1140–1149. - PubMed
    1. Veltkamp R, Korompoki E, Harvey KH, et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2025;405(10482):927–936. 10.1016/S0140-6736(25)00333-2 - DOI - PubMed
    1. Chi K-Y, Li M-Y, Chen C, Kang E, Cochrane T. Ten circumstances and solutions for finding the sample mean and standard deviation for meta-analysis. Systematic Reviews. 2023;12(1):62. - PMC - PubMed
    1. Cates CJ. Simpson’s paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol. 2002;2(1):1. 10.1186/1471-2288-2-1 - DOI - PMC - PubMed

LinkOut - more resources